Vir Biotechnology, INC

Vir Biotechnology announced the departure of its Chief Financial Officer, Jason O'Byrne, effective August 3, 2026, with Brent Sabatini appointed as interim principal financial officer.

Vir Biotechnology has increased its board size to eight members and appointed Timothy Coughlin as a new director and Audit Committee Chair.

Vir Biotechnology reports the resignation of director Saira Ramasastry and the results of its 2026 Annual Meeting.

Vir Biotechnology announced first quarter 2026 financial results, highlighting the closing of its global strategic collaboration with Astellas for VIR-5500 and positive data updates for its chronic hepatitis delta program.

Vir Biotechnology announced that its Executive Vice President and Chief Medical Officer, Mark Eisner, MD, MPH, will be stepping down from his role effective April 24, 2026.

Vir Biotechnology's CEO, Marianne De Backer, has been appointed to the additional role of President, consolidating leadership.

Vir Biotechnology reports a reduced net loss in Q3 2025, driven by cost savings, despite a significant revenue decline, as its key clinical programs advance ahead of schedule.

Vir Biotechnology, Inc. reported a net loss of $110.96 million for Q2 2025, with significant R&D investments in its hepatitis delta and oncology programs, while maintaining strong liquidity.

Vir Biotechnology announces its Q1 2025 financial results, showcasing progress in its clinical programs for hepatitis delta, hepatitis B, and oncology.

Vir Biotechnology announced its Q3 2024 financial results, a strategic restructuring, and provided updates on its clinical pipeline, including a new licensing agreement with Sanofi.

Vir Biotechnology announced its second quarter 2024 financial results, alongside a strategic restructuring and a new licensing agreement with Sanofi.

Vir Biotechnology reported its first quarter 2024 financial results, highlighted by a significant contract revenue increase and pipeline advancements, while also announcing the departure of its CFO.

Vir Biotechnology strengthens its pipeline with a global strategic collaboration for prostate cancer candidate VIR-5500 and an exclusive commercial license for its chronic hepatitis delta treatment in Europe, Australia, and New Zealand, while reporting a net loss of $438.0 million for 2025.

Vir Biotechnology advances its pipeline, focusing on hepatitis delta and oncology, while managing financial realignment and leadership changes.

Vir Biotechnology's 2023 annual report highlights a year of strategic realignment, pipeline advancement, and continued focus on developing treatments for serious infectious diseases.

Director Timothy Coughlin acquired 16,000 shares of restricted stock units and 32,000 stock options in Vir Biotechnology, Inc.

Director Janet Napolitano sold 3,200 shares of Vir Biotechnology, Inc. common stock at a price of $9.45 per share.

Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology, sold 379 shares of common stock on June 1, 2026.

Director Charles Elliott Sigal was granted 8,000 restricted stock units and 16,000 stock options by Vir Biotechnology, Inc.

Director Janet Napolitano acquired 8,000 restricted stock units and 16,000 stock options as part of Vir Biotechnology's equity incentive plan.

Director Robert J. More acquired 8,000 restricted stock units and 16,000 stock options as part of Vir Biotechnology's equity incentive plan.

Vir Biotechnology has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on May 26, 2026.

Vir Biotechnology has filed a definitive proxy statement with the SEC.

Vir Biotechnology's proxy statement details director nominees, executive compensation, and corporate governance practices for the upcoming 2025 Annual Meeting of Stockholders.

Vir Biotechnology details its strategic direction, executive compensation, and board nominees in preparation for the 2024 Annual Meeting of Stockholders.

Vir Biotechnology has filed a definitive proxy statement with the SEC.

Vir Biotechnology's upcoming annual meeting will include the election of directors and an advisory vote on executive compensation.

Vanguard Portfolio Management has reported a beneficial ownership of 6.85% in Vir Biotechnology Inc. common stock as of June 30, 2026.

SoftBank Vision Fund entities have reported a 6.5% beneficial ownership stake in Vir Biotechnology, Inc. as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.79% of Vir Biotechnology Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Vir Biotechnology Inc. following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 10.8% in Vir Biotechnology, Inc.'s common stock as of March 31, 2025.